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BAG-1 (also known as HAP; Zeiner et al, 1997) is a multifunc-
tional protein which interacts with and modulates the activity of
functionally diverse targets. BAG-1 was first identified as a BCL-
2-binding protein that cooperated with BCL-2 to suppress apop-
tosis induced by staurosporine, Fas or cytotoxic T-lymphocytes in
Jurkat cells (Takayama et al, 1995) and BAG-1 overexpression
alone or in conjunction with BCL-2 has since been shown to
contribute to suppression of apoptosis induced by diverse stimuli
in a variety of cell types (Clevenger et al, 1997; Schulz et al, 1997;
Takayama et al, 1997; Kullmann et al, 1998). BAG-1 also interacts
with steroid hormone receptors, including the androgen, oestrogen
and glucocorticoid receptors (Zeiner and Gehring, 1995; Froesch
et al, 1998) and the retinoic acid receptor (Liu et al, 1998) and
BAG-1 influences transcriptional activation and apoptosis induced
by steroid hormones and retinoids (Froesch et al, 1998; Kullmann
et al, 1998; Liu et al, 1998). BAG-1 binds some tyrosine kinase
growth factor receptors (the hepatocyte growth factor and platelet
derived growth factor receptors) and enhances the ability of these
receptors to suppress apoptosis (Bardelli et al 1997), and can bind
and activate the RAF-1 serine/threonine kinase (Wang et al, 1996).
BAG-1 interacts with the human homologue of Drosophila seven
in absentia (Siah) and inhibits p53-mediated growth arrest
(Matsuzawa et al, 1998). Finally, BAG-1 binds directly and tightly
to HSP/HSC70 heat shock proteins and modulates their chaperone
activity (Hohfeld and Jentsch, 1997; Takayama et al, 1997; Zeiner
et al, 1997). It is possible that binding to some BAG-1 partners, for
example, the oestrogen receptor (ER), may be mediated by heat
shock proteins, since HSP70 has been identified in ER complexes
(Landel et al, 1994). Thus, BAG-1 potentially regulates several
important cell growth control pathways.
The prototypical BAG-1 proteins in murine and human cells
have molecular masses of approximately 32 kDa and 36 kDa
respectively (Takayama et al, 1995, 1996; Packham et al, 1997).
More recently, we and others identified novel higher molecular
weight BAG-1 isoforms in human and mouse cells (Zeiner and
Gehring, 1995; Packham et al, 1997; Takayama et al, 1998).
Human and mouse cells express an approximately 50 kDa form,
and an approximately 46 kDa form (also called RAP46; Zeiner
and Gehring, 1995) has additionally been observed in human cells.
These BAG-1/HAP isoforms have been referred to as p50, p46 and
p36 BAG-1 (Packham et al, 1997) or as BAG-1L, BAG-1M and
BAG-1 respectively (Takayama et al, 1998). The larger molecular
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weight isoforms are generated by translation initiation at upstream
codons and have unique N-terminal sequences relative to the
major isoform (Packham et al, 1997; Takayama et al, 1998). The
50 kDa isoform is generated by initiation at a CUG codon
whereas, like the prototypical BAG-1 isoform, the 46 kDa form
initiates at a AUG codon. All BAG-1 isoforms contain a ubiquitin-
like domain and varying numbers of a six amino-acid repeat
(Takayama et al, 1995, 1998; Packham et al, 1997) although the
functional significance of these motifs is not known. Two potential
nuclear localization sequences (NLS) have been identified in
BAG-1 isoforms. Mouse and human p50 isoforms uniquely
contain a sequence which is very similar to the NLS of SV40 large
T antigen and nucleoplasmin (Packham et al, 1997; Takayama
et al, 1998). All human BAG-1 proteins also contain a potential
bipartite NLS, but this sequence is relatively poorly conserved in
mouse (Zeiner and Gehring, 1995; Packham et al, 1997). Although
the major p36/p32 BAG-1 isoforms localize to the cytoplasm and
p50 is predominantly present in the nucleus (Packham et al, 1997;
Takayama et al, 1998), the roles of these potential NLS have not
been addressed.
Regulation of cell proliferation and survival by oestrogens is a
key component of growth control of normal and malignant breast
epithelial cells, and ER status is an important prognostic and predic-
tive marker of response to hormone therapy in human breast cancer.
Oestrogens function primarily by binding to and activating the ER
which is a ligand-dependent transcription factor. Following
hormone depletion or treatment with anti-oestrogens, cells withdraw
from the cell cycle and/or undergo cell death (Bardon et al 1987;
Lippman and Dickson, 1989; Kyprianou et al, 1991; Wilson et al,
1995). Although there is some conflicting evidence, the cell death
following hormone withdrawal appears to be due to activation of
apoptosis (Kyprianou et al, 1991; Wilson et al, 1995). Thus, apop-
tosis and oestrogen-responsive are closely linked pathways in breast
cancer. One pathway by which oestrogens may promote viability of
breast cancer cells is via induction of BCL-2 since BCL-2 expres-
sion in MCF7 breast cancer cells is regulated by oestrogens and
enforced BCL-2 expression suppresses MCF7 cell apoptosis
(Texeira et al, 1995; Huang et al, 1997). This may explain the
frequent co-expression of ER and BCL-2 in breast tumours
(Bharagava et al, 1994; Leek et al, 1994; Silvestrini et al, 1994).
Since sensitivity of breast epithelial cells to apoptosis and
oestrogens are closely linked and key determinants of breast
cancer development and progression, BAG-1 may be important in
breast cancer. For example, BAG-1 may cooperate with relatively
low levels of BCL-2 to provide effective protection from apop-
tosis. BAG-1 may also influence the response of cells to oestro-
gens by direct effects on ER function. The aims of this study are to
investigate the expression of BAG-1 isoforms in normal and
malignant breast cells. We show that multiple BAG-1 isoforms are
highly expressed in some breast cancers and, like BCL-2, their
expression is often associated with positive ER status. However,
expression and subcellular localization of BAG-1 isoforms are not
regulated by oestrogens. BAG-1 may be an important prognostic
marker or therapeutic target in breast cancer.
MATERIALS AND METHODS
Cell lines and cell culture
The breast cancer derived cell lines used in this study were
obtained from ATCC, except SK-BR-3 and -7 cells which were
from the New York (Sloane Kettering) branch of LICR, CAL-51
(Gionanni et al, 1990) which was obtained from the Dutrillaux
Laboratory and GI-101 (Hurst et al, 1993) which was kindly
forwarded by Prof CM Steel. The cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco/Life
Technologies) supplemented with 10% fetal calf serum (FCS). For
experiments requiring depletion of exogenous steroid hormones,
cells were first washed thoroughly in phenol red-free DMEM and
then cultured in phenol red-free DMEM supplemented with 10%
charcoal stripped FCS for 4 days before stimulation with 10 nM
17b-estradiol (Sigma). Purified luminal or myoepithelial cells
were obtained by immunomagnetic separation from clinical
mammoplasty tissue (obtained from the Stephen Kirby Skin Bank)
as previously described (Clarke et al, 1994). This procedure is
based on the exclusive expression of epithelial membrane antigen
(EMA) and CALLA (CD10) on luminal and myoepithelial cells
respectively, and highly enriched cell preparations (> 98% purity)
are isolated using superparamagnetic (MACS) beads. ICI 182 780
was obtained from Tocris (Bristol, UK) and was prepared as a
100 mM stock solution in dimethyl sulphoxide (DMSO).
Tumour sections and immunostaining
All sections were dewaxed in xylene, taken to absolute alcohol
(74OP) and endogenous peroxidase activity blocked with 3%
hydrogen peroxide in methanol for 10 min. Sections were rinsed in
tap water and transferred to a 15 lb per square inch pressure cooker
containing 3 litres of boiling citrate buffer (pH 6.0). The slides
were cooked at full pressure for 2 min and transferred to running
tap water. The sections were blocked in normal goat serum (1/5 in
Tris-buffered saline) for 10 min and incubated overnight at room
temperature with the BAG-1 polyclonal at a final dilution of
1/1000 or for 1 h at room temperature with the ER antibody (clone
1DS) at a final dilution of 1/40. The primary antibodies were
rinsed off in Tris-buffered saline and the slides transferred to a
Dako TechMate instrument for detection. For BAG-1 staining,
slides were incubated in ChemMate Link antibody (biotinylated
goat anti-rabbit antibody) for 30 min and in ChemMate horse-
radish peroxidase (HRP)-conjugated streptavidin for 30 min. ER
staining was detected using the Dako strepAB complex/HRP Duet
system. Slides were incubated in the link antibody and in the
avidin–biotin complex for 35 min. Slides were visualized with
diaminobenzidine, counterstained in Mayer’s haematoxylin and
mounted in synthetic mountant. Sections were processed in
parallel but with the primary antibody omitted as a negative
control in each experiment.
Antibodies and immunoblotting
BAG-1 specific monoclonal and polyclonal antibodies were
prepared using a fusion protein containing human p36 BAG-1
fused to the C-terminus of glutathione-S-transferase (GST) as an
immunogen. Human BAG-1 sequences were amplified in a poly-
merase chain reaction (PCR) using primers V5827 (CGCGGATC-
CGAGATGAATCGGAGCCAG) and T0459 (CCGGGATC-
CTGCTACACCTCACTCGGCCAG) and plasmid p42 (Packham
et al, 1997) as a template. The PCR product was digested using
BamHI and cloned into plasmid pGEX2TK (Pharmacia) which
had been digested with the same restriction enzyme to give
pGEX.BAG-1. BL21 Escherichia coli cells were transformed
with pGEX.BAG-1, GST-BAG-1 expression induced using1044 M Brimmell et al
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isopropyl-b-thiogalactopyranoside and purified using glutathione
sepharose 4B beads (Pharmacia).
The GST-BAG-1 fusion protein was used to repeatedly immu-
nize female New Zealand White rabbits and BALB/c mice for
production of polyclonal and monoclonal antibodies respectively.
Splenocyte fusions were made as previously described using SP2
cells (Fredersdorf et al, 1996) and hybridomas single-cell cloned
by limiting dilution. Clone 3.10 G3 E2 was selected for
immunoblotting analysis of BAG-1 expression.
Western blotting was performed as previously described
(Packham et al, 1997). The BAG-1 monoclonal antibody (clone
3.10 G3 E2) was used as undiluted hybridoma supernatant and the
BAG-1 polyclonal antibody was used at a final dilution of 1/200.
The mouse anti-BCL-2 antibody (C124, Dako) and rabbit anti-ER
antibody (HC-20, Santa Cruz Biotechnology) were used at a final
concentrations of 1 mg ml–1. The green fluorescent protein specific
rabbit antibody (Clontech) was used at a final dilution of 1/2000.
The F1bATPase specific rabbit antisera was a kind gift of Dr W
Neupert (Ludwig-Maximilians Universitat, Munich, Germany)
and was used at a dilution of 1/2000. The histone specific mouse
monoclonal antibody (Chemicon) was used at a final dilution of
1/2000. The HSC70 specific goat antibody (K-19, Santa Cruz
Biotechnology) was used at a final concentration of 0.6 mg ml–1.
The second layer antibodies were donkey HRP-conjugated anti-
rabbit Ig and sheep HRP-conjugated anti-mouse Ig (both
Amersham) at final dilutions of 1/5000, or rabbit HRP-conjugated
anti-goat Ig (Santa Cruz Biotechnology) at a final dilution of
1/2000. BAG-1 isoforms were generated by in vitro translation
using plasmids p42, p276 and p289 as previously described
(Packham et al, 1997).
Cell fractionation
Nuclear, membrane and cytosolic fractions were obtained by
hypotonic lysis and differential centrifugation. Cells were washed
twice in phosphate-buffered saline and resuspended in 1 ml of
hypotonic lysis buffer (10 mM Tris–HCl, pH 7.4; 3 mM calcium
chloride; 2 mM magnesium chloride; 100 mM phenylmethyl-
sulphonyl fluoride; 1 mM aprotinin; 1 mM leupeptin; 1 mM
Na2VO3; 1 mM NaF). After incubation on ice for 10 min, cells
were lysed using a dounce homogenizer. The homogenate was
centrifuged at 500 g for 5 min at 4°C and supernatant removed.
The pellet was resuspended in 0.5 ml of lysis buffer and
centrifuged as before. The two supernatants were combined and
the pellet retained as the nuclear pellet. The supernatant was
centrifuged at 100 000 g for 1 h at 4°C using a TLA45 rotor
(Beckman). The resultant pellet was retained as the membrane
fraction and the supernatant as the cytosolic fraction. Pellets were
resuspended in a volume of lysis buffer equal to the final volume
of cytosol (1.5 ml) and disrupted by brief sonication. A lactate
dehydrogenase (LDH) assay (Sigma Diagnostics) was used to
monitor cytosolic contamination of nuclear and membrane frac-
tions.
Green fluorescent protein fusion constructs
The fluorescent fusion proteins were based upon the EGFP-N1
plasmid (Clontech) which expresses a modified green fluorescent
protein (EGFP) under transcriptional control of cytomegalovirus
immediate early enhancer regulatory sequences. To generate
p36EGFP (which contains the complete p36BAG-1 coding
sequence fused in frame to the 5¢ of EFGP sequences), plasmid
p42 (Packham et al, 1997) was amplified by PCR using primers
Y0075 (CCGGAATTCACCATGAATCGGAGCCAGGAGGTG)
and Y0076 (CGCGGATCCTCGGCCAGGGCAAAGTTTG). To
generate p50NtEGFP (which contains the unique p50BAG-1
N-terminal sequences which are absent from p36BAG-1 fused
in frame to the 5¢ end of EFGP sequences), plasmid p42
(Packham et al, 1997) was amplified using primers W8444
(CCGGAATTCACCATGGCTCAGCGCGGGGGG) and W7882
Table 1 Patient and tumour characteristics
Tumour no. Age Histology Gradea ER status Tumour size/mm Nodal status
96/8797 48 MC I + 32 0/13
96/9382 65 IDC-NST I + 11 NR
96/13497 50 TUB I + 15 NR
96/14922 58 IDC-NST I + 8 NR
96/9031 59 IDC-NST II + 21 3/15
97/1206 57 MC I + 15 0/18
96/10444 46 IDC-NST I + 30 NR
96/13909 57 IDC-NST I + 12 NR
96/7332 57 IDC-NST I + 12 NR
96/11196 51 IDC-NST I + 21 0/12
96/13658 45 IDC-NST II – 22 4/8
96/15630 41 IDC-NST III – 4 4/17
97/2380 49 IDC-NST III – 14 0/16
96/9041 47 IDC-NST III – 29 0/23
96/5863 62 IDC-NST III – 24 0/24
96/9953 26 AM III – 30 0/7
96/9827 84 IDC-NST III – 40 NR
97/12680 60 IDC-NST III – 23 4/10
97/3377 31 IDC-NST II – 11 0/10
97/4880 37 IDC-NST II –b 3N R
MC, mucinous carcinoma; IDC-NST, infiltrating ductal carcinoma, no special type; TUB, tubular carcinoma; AM, atypical medullary carcinoma; NR, no axillary
resection performed; +, ER expressed in >10% of tumour cells; –, ER expressed in <10% of tumour cells. aModified Bloom and Richardson Grading System.
bTumour 97/4880 comprised ER-negative IDC and largely ER-negative carcinoma in situ with focal ER positivity.BAG-1 expression in breast cancer 1045
British Journal of Cancer (1999) 81(6), 1042–1051 © 1999 Cancer Research Campaign
(CGCGGATCCTCTTCGCCCTGGGTCGCC). The amplification
products were digested with EcoRI and BamHI and cloned into
plasmid EGFP-N1 which had been digested with the same
enzymes. MCF7 and SAOS2 osteosarcoma cells were transfected
using the SuperFect reagent (Qiagen) according to the manufac-
turers’ instructions and analysed for EGFP expression by fluores-
cence microscopy and immunoblotting after 24 h.
RESULTS
BAG-1 immunostaining in normal breast epithelia and
breast tumours
We prepared a BAG-1-specific polyclonal antibody which was
suitable for staining of archival paraffin-embedded material. The
specificity of the antibody for BAG-1 isoforms was confirmed by
immunoblot analysis (Figure 1). When tested against lysates
prepared from human breast cancer cell lines (lanes 1 and 2), the
antisera recognized the three previously described human BAG-1
isoforms (p36, p46 and p50 BAG-1) and its reactivity was iden-
tical to other BAG-1 antibodies (c.f. Figure 4). Moreover, the anti-
body specifically recognised all three BAG-1 isoforms generated
by in vitro translation of the human BAG-1cDNA (Packham et al,
1997) (lanes 3–6).
Twenty cases of breast carcinomas were analysed for BAG-1
expression using the BAG-1 specific polyclonal antibody (Table
1). We randomly selected ten ER-positive cases and ten ER-
negative cases from the archives in histopathology at University
Table 2 BAG-1 immunostaining in ER-positive and ER-negative breast
tumours
Tumour no. Associated Associated DCIS IDC
normal benign
tissues lesions
ER-positive tumours
96/8797 + + +
96/9382 + ±±
96/13497 + ± (AC) + +
96/14922 + + (H+SA) + +
96/9031 + ±±
97/1206 + +
96/10444 + + +
96/13909 + ±±
96/7332 +
96/11196 + ± –
ER-negative tumours
96/13658 + ±
96/15630 + ±±
97/2380 + ±
96/9041 + + (H) –
96/5863 + ±
96/9953 + –
96/9827 ±
97/12680 ±±
97/3377 + – –
97/4880 + –/+a ±
DCIS, ductal carcinoma in situ: IDC, inflitrating ductal carcinoma; AC,
apocrine cyst; H, hyperplasia; SA, sclerosing adenosis; –, no detectable
expression; +, positive (>90% cells intense staining); ±, most cells negative
(focal staining [<10% positive cells] or weakly positive at tumour edge).
Blanks indicate material not present in section. aTumour 97/4880 comprised
heterogenous DCIS largely comprised of ER/BAG-1 negative cells with foci
of ER/BAG-1 positivity.
p50
p46
p36
p50
p46
p36
12 3 45 6
Figure 1 Characterization of BAG-1-specific polyclonal antibody.
Immunoblot analysis of BAG-1 isoforms in human breast cancer cell lines
and generated in vitro using rabbit reticulocyte lysates. Lanes 1 and 2, RIPA
lysates (20 mg) prepared from T47D and ZR-75-1 human breast cancer cell
lines respectively. Lanes 3–6 are BAG-1 proteins made in reticulocyte lysates
programmed with plasmids p289 (lane 3), p276 (lane 4) and p42 (lane 5), or
unprogrammed lysate as a negative control (lane 6). The p36, p46 and p50
BAG-1 isoforms are indicated. The fastest migrating band in lanes 3–6
corresponds to endogenous rabbit BAG-1
A
B
C
Figure 2 BAG-1 immunostaining in normal and benign hyperproliferative
breast epithelia. Representative examples of BAG-1 immunostaining in
uninvolved epithelia associated with tumours 97/12680 (A) and 96/14922
(B) and sclerosing adenosis associated with tumour 96/14922 (C)1046 M Brimmell et al
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College London. In addition to the infiltrating ductal carcinoma
(IDC) component of these tumours, BAG-1 immunostaining was
determined in ductal carcinoma in situ (DCIS), associated benign
lesions and adjacent normal breast epithelia. Similar immuno-
staining results were obtained using BAG-1-specific monoclonal
antibodies and immunostaining of the polyclonal antibody was
specifically ablated by incubation with GST-BAG-1, but not GST
(data not shown).
BAG-1 was detected in 18/18 (100%) of normal breast tissues
examined. BAG-1 was readily detected in luminal cells, whereas
staining was less intense or absent in myoepithelial cells, and
BAG-1 was undetectable in surrounding lymphocytes and stromal
cells (Figure 2 A,B). A recent survey of BAG-1 expression in
normal human tissues showed a similar pattern of BAG-1 expres-
sion predominantly in luminal epithelial cells of the breast
(Takayama et al, 1998). Cells showed a predominantly cyto-
plasmic or cytoplasmic plus nuclear distribution of BAG-1
staining. BAG-1 expression was also detected in associated benign
lesions, including sclerosing adenosis (Figure 2C). A summary of
BAG-1 expression is presented in Table 2.
BAG-1 was detected in 9/10 (90%) of ER positive tumours
(Figure 3 A,B). 6/10 of cases showed very intense staining in
essentially all tumour cells, whereas in the remaining cases, BAG-
1 was detectable but staining was weaker and/or focal (3/10 cases)
or undetectable (1/10 cases). In most cases, both DCIS and IDC
components were positive; one case was positive for BAG-1
expression in DCIS only. Again tumour cells showed a predomi-
nantly cytoplasmic or cytoplasmic plus nuclear distribution and in
some cases, BAG-1 expression appeared to be somewhat stronger
in tumour cells relative to uninvolved adjacent epithelia.
In contrast to the ER-positive tumours, BAG-1 was less readily
detectable in the ten ER-negative cases (Figure 3 C, D). BAG-1
was completely undetectable in 3/10 cases (but was detected in
surrounding normal tissue) and in the other seven cases, BAG-1
expression was either weakly positive only at the tumour margin
(two cases) or weakly expressed only at focal points (< 10% posi-
tive cells; five cases). No ER-negative tumour stained as strongly
as the intense staining observed in most ER-positive tumours.
Interestingly, one tumour (97/4880) contained DCIS which was
largely comprised of ER-negative cells but with focal ER posi-
tivity. BAG-1 expression was restricted to ER-positive cells
(Table 2). Therefore, BAG-1 is expressed at high levels in normal
breast epithelia and in some breast tumours, and its expression is
often correlated with positive ER status.
BAG-1 isoform expression in breast cancer cell lines
To further explore the pattern of BAG-1 isoform expression in
breast cancer cells, we used a BAG-1-specific monoclonal anti-
body to analyse a panel of cell lines derived from breast cancers
and preparations of normal breast epithelial cells. BAG-1 isoforms
were detected in all cell lines and preparations at varying levels
(Figure 4 A, B). BAG-1 was expressed at very low levels in
CAL51, CAMA1, SK-BR-7 and BT20 cells and at the highest
level in ZR-75-1, MCF7, MDA-MB-453 and GI-101 cells.
Consistent with results of immunostaining, BAG-1 expression was
AC
BD
Figure 3 BAG-1 is readily detectable in ER-positive, but not ER-negative, breast carcinomas. Representative example of (A) BAG-1 and (B) ER expression in
an ER-positive tumour (96/14922) and (C) region of weak/focal BAG-1 expression and (D) lack of ER expression in an ER-negative tumour (97/12680)BAG-1 expression in breast cancer 1047
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lower in normal myoepithelial cells than in luminal cells and
BAG-1 expression in normal cells was low relative to many cell
lines.
Multiple BAG-1 isoforms were detected in each sample (Figure
4). p36 BAG-1 was generally the most abundant isoform and its
levels differed significantly between cell lines. Expression of the
larger isoforms was generally lower and more consistent between
cell lines relative to variations in p36 BAG-1. However, in cell
lines such as BT20, CAL51 and CAMA1 with low levels of p36,
the larger isoforms were at least as abundant as p36 BAG-1. Of the
larger isoforms, some cell lines expressed only p50 with only very
low level of p46, whereas others expressed approximately equal
amounts of p46 and p50.
We also examined expression of the BAG-1 binding proteins,
BCL-2, ER and the constitutive 70 kDa heat shock protein,
HSC70, in the panel of cell lines (Figure 4B). BCL-2 expression
was also variable in the cell lines and 734B, ZR-75-1, GI-101 and
CAL51 had the highest levels of expression. ER was readily
detected in four cell lines, T47D, 734B, MCF7 and ZR-75-1.
Consistent with previous reports (Lippman et al, 1976; Engel et al,
1978; Chalbos et al, 1982; Coradini et al, 1991), the ER was func-
tional in each of the lines with high level ER expression since
oestrogen induced S phase entry and/or activated ER-dependent
transcription in these cells (data not shown). Therefore, similar to
the tumour sections, there was a correlation between ER status and
BAG-1 expression; all cell lines with high level functional ER
expression also expressed high levels of BAG-1 isoforms. HSC70
was readily detectable in all lines and expression levels did not
vary significantly.
Effects of oestrogen on BAG-1 and BCL-2 expression
in MCF7 cells
One explanation for the correlation between BAG-1 and ER
expression in tumours and cell lines was that BAG-1 expression is
oestrogen-responsive. Indeed, BCL-2 is regulated by oestrogens in
breast cancer cells (Texeira et al, 1995; Huang et al, 1997) and
BAG-1 and BCL-2 are co-regulated in some systems (Adachi et al,
1996). We therefore examined effects of modulating oestrogen
signalling on BAG-1 and BCL-2 expression in oestrogen-respon-
sive MCF7 cells. We first analysed cells grown in normal condi-
tions (phenol red containing medium and complete FCS) and cells
additionally exposed for 2 or 4 days to the pure anti-oestrogen ICI
182 780 (Wakeling et al, 1991). Consistent with previous reports
(Texeira et al, 1995; Huang et al, 1997), exposure of MCF7 cells to
ICI 182 780 significantly down-regulated BCL-2 expression
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Figure 4 (A) Expression of BAG-1 isoforms in preparations of primary
luminal (LUM) and myoepithelial (MYO) cells derived from normal breast.
(B) Expression of BAG-1 isoforms, BCL-2, ER, HSC70 and F1bATPase (as a
loading control) in a panel of breast cancer-derived cell lines. SK-BR-7 cells
were not tested for HSC70 expression. The lower molecular weight bands
detected by the ER antibody in this experiment are due to cross-reactions
and were not detected in other experiments. Two exposures of the BAG-1
blot are shown to more clearly demonstrate expression of p46 and p50
isoforms and low level expression of p36 BAG-1 in CAL51 and CAMA1 cells
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Figure 5 BCL-2, but not BAG-1 expression is regulated by oestrogens in
MCF7 cells. MCF7 cells were cultured in standard growth conditions (DMEM
with phenol red and complete FCS) (lane 1), standard growth medium plus
carrier (DMSO) for 2 or 4 days (lanes 2 and 3), standard growth medium plus
ICI 182 780 (50 nM) for 2 or 4 days (lanes 4 and 5) or were cultured in
hormone depleted conditions (phenol red-free DMEM plus charcoal-stripped
FCS) for 5 days (lane 6) and then treated with 10 nM 17b-oestradiol for 2 or
5 days (lanes 7 and 8). Cells were analysed for expression of BAG-1, BCL-2
and F1bATPase (as a control) by immunoblotting1048 M Brimmell et al
British Journal of Cancer (1999) 81(6), 1042–1051 © 1999 Cancer Research Campaign
(Figure 5). By contrast, BAG-1 expression was not altered. We
also analysed cells which had been deprived of exogenous steroid
hormones (cultured in medium lacking phenol red and supple-
mented with charcoal stripped FCS for 5 days) and then restimu-
lated for 2 or 5 days with 17b-oestradiol. Under these conditions,
BCL-2 expression was significantly elevated after 5 days, whereas
BAG-1 expression was not altered. Therefore, the steady-
state expression levels of BAG-1 isoforms are not coordinately
regulated with BCL-2, and their expression is independent of
oestrogen. Similar results were obtained using oestrogen-
responsive T47D cells (data not shown).
Analysis of the subcellular localization of BAG-1
isoforms
We analysed the localization of BAG-1 isoforms using differential
centrifugation and green fluorescent protein (GFP) fusion proteins
to determine whether they were differently localized in human
breast cancer cells and whether this was regulated by oestrogens.
MCF7 cells were cultured in normal growth conditions and
subcellular fractions prepared by differential centrifugation. Lysis
was performed in the absence of detergents which have previously
been shown to remove BCL-2 family proteins from membranes
and might alter apparent localization of BAG-1 proteins. The
36 kDa isoform was predominantly present in the cytosol (Figure
6, second panel). The relatively small amount of p36 BAG-1
detected in the nuclear fraction (Figure 6) was consistent with the
degree of cytosolic contamination as measured using LDH assays
suggesting that p36 BAG-1 is exclusively present in the cytosol in
MCF-7 cells. The 50 kDa isoform localized to the cell nucleus,
whereas the 46 kDa isoform was present in both cytosolic and
nuclear fractions. Although the nuclear fraction was heavily conta-
minated with mitochondria (presumably a result of the necessity to
avoid detergents in the fractionation procedure), p50 and p46 were
not detected in mitochondrial fractions (despite presence of
F1bATPase reactivity) and their apparent localization to nuclei is
likely to be real and not a result of mitochondrial contamination of
these fractions. As previously described, BCL-2 localized to
nuclear/membrane fractions (Reed, 1997).
We transfected MCF7 cells with expression plasmids encoding
BAG-1/GFP fusion proteins to study localization in intact cells.
The p50 BAG-1 isoform is unique in that its N-terminus contains a
nuclear localization motif absent in other isoforms (Packham et al,
1997). To determine whether the unique N-terminus of p50 BAG-
1 was sufficient to direct nuclear localization, we overexpressed a
GFP fusion protein containing just these sequences. Whereas, the
parental GFP localized in both the cell nucleus and cytosol (Figure
7), the p50 Nt-GFP protein was almost entirely localized to the cell
nucleus and was focused at subdomains consistent with nucleoli.
Therefore, the unique N-terminal sequences present in p50 BAG-1
are sufficient to confer nuclear localization. Localization of a
fusion protein containing the p36 BAG-1 portion of BAG-1 was
essentially identical to GFP. Western analysis demonstrated
expression of GFP fusion proteins of the expected molecular
masses in transfected cells (Figure 7D).
To test whether localization of BAG-1 isoforms was regulated
by oestrogens, we fractionated MCF7 cells maintained in the
presence or absence of ICI 182 780. The localization of BAG-1
isoforms was not altered by these conditions (Figure 6). Similarly,
the distribution of endogenous BAG-1 isoforms was not altered by
culture in hormone depleted conditions or hormone depleted
condition plus 17b-oestradiol and the distribution of GFP/BAG-1
fusion proteins in transfected cells was also independent of culture
conditions (data not shown). Therefore, although BAG-1 isoforms
are differentially localized in breast cancer cells, this is indepen-
dent of oestrogens.
DISCUSSION
Here we have examined expression and regulation of BAG-1
isoforms in primary breast tumours and cell lines. Since BAG-1
interacts with BCL-2 and ER, and may influence sensitivity of
breast cancer cells to apoptosis and steroid hormones, analysis of
BAG-1 in breast cancer is of significant interest. BAG-1 was
readily detected in normal breast epithelia and most ER-positive
tumours. By contrast, BAG-1 expression was either undetectable
or weak and/or focal in ER-negative tumours. Thus, high levels of
BAG-1 expression are often associated with ER positivity in breast
tumours. It is not clear whether tumours with no BAG-1 detectable
by immunostaining are truly negative for BAG-1 expression. The
expression of BAG-1 in all breast cancer cell lines (albeit at
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Figure 6 Subcellular localization of BAG-1 isoforms in breast cancer cells.
MCF7 cells were cultured in normal conditions (DMEM containing phenol red
and complete FCS; control), normal conditions plus 0.05% DMSO or normal
conditions plus ICI 182 780 (50 nM). Cells were collected after 2 days and
fractionated into (N) nuclear, (M) heavy membrane and (C) cytosolic fractions
by differential centrifugation. Equal volumes of each fraction were analysed
by immunoblotting using BAG-1, BCL-2, histone (marker for nuclei) and
F1bATPase (marker for mitochondria) specific antibodies. Assays for the
cytosolic marker LDH were performed on each fraction and revealed that
less than 20% of total LDH activity was contaminating the nuclear or
membrane fractions. Two exposures of the BAG-1 immunoblot are shown to
more clearly illustrate localization of p46 and p50 BAG-1 isoformsBAG-1 expression in breast cancer 1049
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relatively low levels in some cases) suggests that BAG-1 is
expressed in apparently BAG-1-negative tumours but below the
level of detection of immunostaining. Regardless, there are clearly
significant differences in expression of BAG-1 between individual
breast tumours and this may be important. It is also possible that
differences in subcellular distribution of BAG-1 immunostaining
may be significant.
All normal and breast cancer cells expressed multiple BAG-1
isoforms and, similar to other cell types (Packham et al, 1997;
Takayama et al, 1998) these are differently localized in MCF7
cells. p36 BAG-1 was the predominant isoform in most cells,
although in some cell lines with low levels of p36, the higher
molecular weight isoforms were also relatively abundant.
Consistent with the presence of a sequence very similar to the
nuclear localization sequence of SV40 large T antigen (Packham
et al, 1997), the p50 isoform localized to the nucleus and analysis
of GFPs suggested it was concentrated in subdomains consistent
with nucleoli. The p36 isoform localized to the cytosol, whereas
the p46 isoforms appeared to be distributed between cytoplasmic
and nuclear fractions. A GFP fusion protein containing the p36
BAG-1 isoform was not distributed differently to GFP. Therefore,
whereas the N-terminal NLS present only in p50 BAG-1 is suffi-
cient to direct nuclear localization, the potential bipartite NLS
present in all human BAG-1 isoforms (Zeiner and Gehring, 1995)
is not, at least in these settings.
It is well established that BCL-2 expression strongly correlates
with ER status (Bharagava et al, 1994; Leek et al, 1994; Silvestrini
et al, 1994) and one would therefore predict a similar correlation
between expression of BCL-2 and BAG-1. Consistent with this, all
cell lines with functional ER co-expressed high levels of BAG-1
and BCL-2. BAG-1 and BCL-2 may therefore act as a couple in
ER-positive breast cancer cells and cooperate in regulation of
apoptosis. There is, however, a significant difference between
expression of BCL-2 and BAG-1 in breast epithelial cells, since
whereas the association between ER and BCL-2 may be explained
by positive effects of oestrogens on BCL-2 expression (Texeira
et al, 1995; Huang et al, 1997), BAG-1 is not coordinately
regulated with BCL-2 by oestrogens and both the steady-state
expression and subcellular localization of BAG-1 appears to be
independent of oestrogens. Some ER-negative cell lines also had
high expression of BCL-2 and/or BAG-1 suggesting a complex
mode of regulation.
A key question that emerges from these studies is what is the
functional significance of BAG-1 in normal and malignant breast
cells? BAG-1 is multifunctional and the function of the individual
isoforms may depend on both cell context and expression level.
Positive effects of p50 BAG-1 isoforms on androgen receptor-
dependent transcription and negative effects of p46 BAG-1 on
glucocorticoid receptor-dependent transcription have been
described (Froesch et al, 1998; Kullmann et al, 1998). Therefore,
BAG-1 isoforms may also contribute to or modulate ER respon-
siveness of breast epithelial cells, possibly via effects on 70-kDa
heat shock proteins which are detected in ER complexes (Landel
et al, 1994). High level BAG-1 expression in ER-positive tumours
may potentiate or limit activation of ER by hormone and therefore
be important in determining the level of ER functionality. BAG-1
may also modulate the response of ER complexes to anti-oestro-
gens. To data, effects of BAG-1 on steroid hormone receptors have
been limited to the higher molecular weight isoforms (Froesch
et al, 1998; Kullmann et al, 1998), and the major BAG-1 isoform
may play a distinct function. It is also possible that BAG-1
influences other steroid hormone receptors in breast cancers. For
example, the glucocorticoid receptor was expressed in all cells
examined (data not shown). However, the close correlation
between BAG-1 and ER expression perhaps suggests that the ER
is the most likely receptor target of BAG-1 function in this setting.
HSC70 is a direct binding partner of BAG-1 and may mediate
BAG-1 activities (Hohfeld and Jentsch, 1997; Takayama et al,
1997; Zeiner et al, 1997). However, HSC70 expression was
invariant in the panel of breast cancer cell lines.
AB C
123
D
Figure 7 Analysis of BAG-1 localization using green fluorescent fusion proteins. MCF7 cells maintained in DMEM (with phenol red and complete FCS) were
transfected with plasmids expressing (A) EGFP, (B) p36BAG-1 fused to EGFP or (C) p50 unique N-terminal sequences fused to EGFP. After 24 h, cells were
examined directly by fluorescence microscopy. (D) Immunoblot analysis using anti-GFP antibody of EGFP proteins in transiently transfected SAOS2 cells. Lane
1, EGFP; lane 2, p36BAG-1/EGFP; lane 3, p50Nt/EGFP1050 M Brimmell et al
British Journal of Cancer (1999) 81(6), 1042–1051 © 1999 Cancer Research Campaign
As mentioned above, BAG-1 may also function by directly
influencing apoptosis of breast cancer cells in a BCL-2-dependent
manner. BCL-2 proteins are thought to function, at least in part, by
inserting into membranes and contributing to the formation or
regulation of channels. It has been hypothesized that BAG-1 may
alter BCL-2 function by acting on heat shock proteins which may
facilitate conformational changes of BCL-2 itself or proteins
which might pass through the BCL-2-dependent channels (Reed,
1997). Thus, breast cancer cells may be effectively protected from
apoptosis by a relatively low level of BCL-2 in conjunction with
significant BAG-1 expression. In addition, BAG-1 binds and
modulates function of hepatocyte growth factor receptor (Bardelli
et al, 1997) which may also be important in breast carcinogenesis
(Tuck et al, 1996; Beviglia et al, 1997) and represent another
potential target of BAG-1 in breast cancer.
The expression of BAG-1 was higher in some cell lines than in
preparations of normal breast epithelial cells. In some ER-positive
cases, BAG-1 staining in tumour cells was more intense than in
surrounding normal cells. Overexpression of BAG-1 may there-
fore contribute to development of some ER-positive breast
cancers. Conversely, BAG-1 expression was often reduced in
ER-negative tumour cells relative to normal cells. A recent report
also noted overexpression of BAG-1 relative to normal cells in
some tumours although no analysis of ER was attempted in this
study (Zapata et al, 1998). The highly variable expression of BAG-
1 in breast cancers may be a useful prognostic/predictive marker.
For example, not all ER-positive tumours respond to hormone
therapy and it is possible that analysis of BAG-1 expression, in
addition to other markers of ER function, may be of benefit in
predicting response of individual tumours to hormone therapy.
BAG-1 may also be important for growth of tumours via direct
effect of ER or BCL-2-dependent suppression of apoptosis and
BAG-1 may be an attractive target for therapeutic intervention in
tumours. Although further studies are required to address these
issues, breast cancer cells provide a biologically relevant system to
dissect the functional roles of different BAG-1 isoforms.
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